



SPARC/Sec/SE/2018-19/052

11th January 2019

To

National Stock Exchange of India Ltd.

Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Limited

P J Towers,
Dalal street,
Mumbai - 400001

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: Updates: Achievement of milestone – Commercialisation of XELPROS™

Dear Sir/Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we are pleased to inform you that consequent to the receipt of US FDA Approval, as informed vide our Press Release dated 14th September 2018, Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" which includes its subsidiaries and/or associate companies) has informed SPARC about commercialisation of XELPROS™ (Latanoprost ophthalmic emulsion) 0.005%.

SPARC had out-licensed XELPROS™ to Sun Pharma in June 2015 and this commercialisation of XELPROS™, has triggered a milestone payment of USD 10 Million and sales linked royalties, by Sun Pharma to SPARC.

Kindly take the above on record.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

Debashis Dey

Company Secretary

Sun Pharma Advanced Research Company Ltd.

17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India.

Tel.: (91-22) 6645 5645 | Fax.: (91-22) 6645 5685 | CIN: L73100GJ2006PLC047837 | Website: www.sparc.life

Registered Office : SPARC, Akota Road, Akota, Vadodara - 390 020, Gujarat, India.